Drug Approval | April 07, 2024
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
The Product is expected to be the first generic approval on the market
The Product is expected to be the first generic approval on the market
Highly effective preservation solutions ensuring the safety and protection of personal care products
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Application based on results from the TROPION-Breast01 Phase III trial
Subscribe To Our Newsletter & Stay Updated
